Business
Bionano Reports Second Quarter 2023 Results and Highlights Recent Business Progress
Q2 2023 revenue was $8.7 million, which represents a 30% increase over Q2 2022Installed base of Saphyr® systems totaled 281 as of June 30, 2023, which
About this update from Bionano Genomics, Inc.
[{"type":"text","content":"Q2 2023 revenue was $8.7 million, which represents a 30% increase over Q2 2022Installed base of Saphyr® systems totaled 281 as of June 30, 2023, which represents a 43% increase over Q2 2022Sold 7,062 nanochannel array flowcells as of June 30, 2023, which represents a 108% increase over the number of flowcells sold in Q2 2022Conference call today, August 9th, 2023, at 4:30 PM ET SAN DIEGO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the second quarter ended June 30, 2023. Q2 2023 Highlights Installed base of Saphyr® systems totaled 281 at the end of the second quarter 2023, which was an increase of 22 systems over the first quarter of 2023 and represents a 43% increase over the 196 installed systems reported at the end of the second quarter of 2022.7,062 nanochannel array flowcells sold during the second quarter, which represents a 35% increase over the 5,226 flowcells sold during the first quarter of 2023 and represents an increase of 108% over the 3,394 flowcells sold during the second quarter of 2022.Announced the commercial release of new kits for the Ionic® Purification System featuring new chemistry for nucleic acid extraction from formalin-fixed paraffin-embedded (FFPE) and tumor tissue. These products offer potential improvements in quality and yield of nucleic acid extracted from complex biological samples including those with low cell counts or otherwise challenging sample types, such as FFPE tumor samples.Announced the Stratys™ system for high throughput optical genome mapping (OGM), which will enable a four-fold increase in raw data generation rate compared to the Saphyr® instrument. The Stratys instrument is compatible with the Company’s latest G2 chemistry and is designed for maximum lab flexibility by enabling up to 12 single access chips, accessible as they complete runs, without the need to batch multiple samples on a consumable. Announced VIA™ software, which replaces NxClinical™ software with a simple and integrated workflow for visualization, interpretation and reporting for hematologic malignancies across OGM, microarray and next-generation sequencing (NGS) data types for enhanced contextualization across multiple variant types and accelerated time to results at a reduced cost. A workflow focused on genetic disease is expected later in 2023. Ann...